ES2994095T3 - Saracatinib for use in the treatment of idiopathic pulmonary fibrosis - Google Patents

Saracatinib for use in the treatment of idiopathic pulmonary fibrosis Download PDF

Info

Publication number
ES2994095T3
ES2994095T3 ES20710607T ES20710607T ES2994095T3 ES 2994095 T3 ES2994095 T3 ES 2994095T3 ES 20710607 T ES20710607 T ES 20710607T ES 20710607 T ES20710607 T ES 20710607T ES 2994095 T3 ES2994095 T3 ES 2994095T3
Authority
ES
Spain
Prior art keywords
saracatinib
ipf
pharmaceutically acceptable
acceptable salt
nintedanib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20710607T
Other languages
English (en)
Spanish (es)
Inventor
Leslie Cousens
Chad Nivens
Katherine Jane Escott
Susan Monkley
Antje Prasse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
AstraZeneca AB
Original Assignee
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV, AstraZeneca AB filed Critical Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Application granted granted Critical
Publication of ES2994095T3 publication Critical patent/ES2994095T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES20710607T 2019-02-27 2020-02-26 Saracatinib for use in the treatment of idiopathic pulmonary fibrosis Active ES2994095T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962811009P 2019-02-27 2019-02-27
PCT/IB2020/051642 WO2020174420A1 (en) 2019-02-27 2020-02-26 Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor

Publications (1)

Publication Number Publication Date
ES2994095T3 true ES2994095T3 (en) 2025-01-17

Family

ID=69784492

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20710607T Active ES2994095T3 (en) 2019-02-27 2020-02-26 Saracatinib for use in the treatment of idiopathic pulmonary fibrosis

Country Status (12)

Country Link
US (1) US20220117966A1 (https=)
EP (1) EP3930715B1 (https=)
JP (2) JP7547356B2 (https=)
CN (1) CN113811296B (https=)
DK (1) DK3930715T3 (https=)
ES (1) ES2994095T3 (https=)
FI (1) FI3930715T3 (https=)
HU (1) HUE067967T2 (https=)
MA (1) MA55076A (https=)
PT (1) PT3930715T (https=)
TW (1) TWI836022B (https=)
WO (1) WO2020174420A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112674031B (zh) * 2020-12-03 2021-11-30 同济大学 新型冠状病毒感染的啮齿动物模型的构建方法和用途
US20250161250A1 (en) * 2022-02-28 2025-05-22 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
CN117618436A (zh) * 2022-08-25 2024-03-01 广州再极医药科技有限公司 一种稠环嘧啶类化合物的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
US9844528B2 (en) * 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
CN102675282B (zh) * 2011-03-15 2014-12-24 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
US20130336889A1 (en) * 2012-06-14 2013-12-19 National Taiwan University Nanoparticle and method for detecting or treating a tumor using the same
CN105294682B (zh) * 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
EP4653015A3 (en) * 2015-01-26 2025-12-31 Yale University COMPOSITIONS AND METHODS OF USE OF TYROSINE KINASE INHIBITORS
EP3277282B1 (en) * 2015-04-01 2022-10-12 Istanbul Universitesi Rektorlugu Dasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases
GB201514760D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
JP6905662B2 (ja) * 2015-11-14 2021-07-21 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換キノリン化合物の結晶形およびその医薬組成物
EP3228630A1 (en) * 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
WO2018026441A1 (en) * 2016-08-01 2018-02-08 The Regents Of The University Of California Methods for preventing or treating fibrotic diseases
WO2018046876A1 (en) * 2016-09-06 2018-03-15 The University Of Birmingham Treatment of chronic inflammatory disease
CN106692150B (zh) * 2016-12-21 2019-08-20 中国人民解放军第三〇二医院 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途
EP3964214A1 (en) * 2020-09-02 2022-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Modulators of airway basal cells for the treatment or prevention of lung diseases

Also Published As

Publication number Publication date
CN113811296A (zh) 2021-12-17
PT3930715T (pt) 2024-08-02
MA55076A (fr) 2022-04-20
DK3930715T3 (da) 2024-08-05
TWI836022B (zh) 2024-03-21
EP3930715B1 (en) 2024-05-08
HUE067967T2 (hu) 2024-12-28
JP2024174909A (ja) 2024-12-17
FI3930715T3 (fi) 2024-08-05
CN113811296B (zh) 2025-05-16
EP3930715A1 (en) 2022-01-05
JP2022521635A (ja) 2022-04-11
JP7547356B2 (ja) 2024-09-09
WO2020174420A1 (en) 2020-09-03
TW202045180A (zh) 2020-12-16
US20220117966A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
KR102539920B1 (ko) 종양-치료용 약제학적 조성물
ES2994095T3 (en) Saracatinib for use in the treatment of idiopathic pulmonary fibrosis
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
US20120157472A1 (en) Method for treating colorectal cancer
US20190022225A1 (en) Protocol for increasing life expectancy in a test subject
ES2848710T3 (es) Nuevo uso de compuestos agonistas del receptor sigma-1
AU2018285822B2 (en) Tinostamustine for use in treating sarcoma
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
BR112020001916A2 (pt) combinação terapêutica de um inibidor de tirosina quinase de egfr de terceira geração e um inibidor de raf
US11439646B2 (en) Anti-proliferative agents for treating PAH
KR20210150495A (ko) 심혈관 기능장애의 성별-의존적 치료를 위한 방법 및 재료
KR20240001703A (ko) 유비퀴틴 특이적 펩티다제 22 (usp22)의 억제제 및 질환 및 장애를 치료하기 위한 그의 용도
CN113631179A (zh) 用于治疗特发性肺纤维化的方法
US12174172B2 (en) Method for evaluating the efficacy of a composition in reducing the effects of cancer therapeutics on skin
WO2025229127A1 (en) A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
JP5437331B2 (ja) 心臓機能を改善するための医薬組成物及びその方法
WO2025202854A1 (en) Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
JP2024500628A (ja) 腫瘍治療のための４－アミノ－ｎ－［４－（メトキシメチル）フェニル］－７－（１－メチルシクロプロピル）－６－（３－モルホリノプロパ－１－イン－１－イル）－７ｈ－ピロロ［２，３－ｄ］ピリミジン－５－カルボキサミドの使用法
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов